These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 23358791)

  • 1. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.
    Bonkat G; Müller G; Braissant O; Frei R; Tschudin-Suter S; Rieken M; Wyler S; Gasser TC; Bachmann A; Widmer AF
    World J Urol; 2013 Dec; 31(6):1427-32. PubMed ID: 23358791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-Acquired Uropathogenic
    Carmona-Cartaya Y; Hidalgo-Benito M; Borges-Mateus LM; Pereda-Novales N; González-Molina MK; Quiñones-Pérez D
    MEDICC Rev; 2022 May; 24(2):20-25. PubMed ID: 35648059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric community acquired urinary tract infections due to extended-spectrum beta-lactamase versus non-extended-spectrum beta-lactamase producing bacteria.
    Alsubaie MA; Alsuheili AZ; Aljehani MN; Alothman AA; Alzahrani AS; Mohammedfadel HA; Alnajjar AA
    Pediatr Int; 2023; 65(1):e15620. PubMed ID: 37735838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients].
    Marković T; Jeinić L; Smitran A; Petković M
    Srp Arh Celok Lek; 2013; 141(11-12):775-9. PubMed ID: 24502096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and risk factors for extended-spectrum β-lactamase producing antimicrobial-resistant
    Omar MH; Kilale AM; Rashid HK; Mwakapeje ER; Onoka IM; Gimbi AA
    Pan Afr Med J; 2024; 47():193. PubMed ID: 39119113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
    Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
    BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
    Meier S; Weber R; Zbinden R; Ruef C; Hasse B
    Infection; 2011 Aug; 39(4):333-40. PubMed ID: 21706226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011.
    Zykov IN; Sundsfjord A; Småbrekke L; Samuelsen Ø
    Infect Dis (Lond); 2016 Feb; 48(2):99-107. PubMed ID: 26414659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
    Rodríguez-Avial C; Rodríguez-Avial I; Hernández E; Picazo JJ
    Rev Esp Quimioter; 2013 Mar; 26(1):43-6. PubMed ID: 23546462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K; Grey J; Fronczek C; Marr K
    Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive
    Park KS; Kim DR; Baek JY; Shin A; Kim KR; Park H; Son S; Cho H; Kim YJ
    J Korean Med Sci; 2023 Dec; 38(48):e361. PubMed ID: 38084025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.
    Bahramian A; Eslami G; Hashemi A; Tabibi A; Heidary M
    Acta Microbiol Immunol Hung; 2018 Mar; 65(1):15-25. PubMed ID: 29137487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiology and Drug Resistance of Pathogens in Patients Hospitalized at the Nephrology Department in the South of Poland.
    Michno M; Sydor A; Wałaszek M; Sułowicz W
    Pol J Microbiol; 2018; 67(4):517-524. PubMed ID: 30550238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.